EpiCARE Research Council – Current Grant Opportunities

Link

Closing date 1: Friday, August 21, 2026. 

Budget: $500,000 over 3 years (beginning January 1 of each year). Indirect costs must be included within the $500,00 budget and are not to exceed 10% of the total award.

DSF Basic and Translational Priority Areas include:

• Understanding the mechanisms of epileptogenesis in Dravet syndrome
• Development of enhanced models to study Dravet syndrome
• Understanding of the cellular, molecular, and genetic mechanisms that contribute to the pathogenesis of Dravet syndrome
• Revealing causes and interventions for seizures and comorbidities in Dravet syndrome
• Understanding causes and developing interventions for SUDEP
• Development of novel treatments and interventions that will prevent the onset or halt the progression of Dravet syndrome; this includes research that may overcome the current size and delivery hurdles for gene-therapy approaches

DSF Clinical Priority Areas include:

• Research that helps better characterize the natural history of Dravet syndrome across the patient lifetime, including identifying patient trends, characteristics, epidemiology, or other clinical aspects of Dravet syndrome and/or its comorbidities
• Research that develops or refines outcome measurements that can fully reflect meaningful improvements in patient symptoms and quality of life
• Research that helps to understand, predict, and prevent SUDEP
• Research that will encourage the development of novel therapies to prevent onset or halt the progression of the Dravet syndrome

Link

Deadline: still under development, will be launch in summer 2026

The action under this topic must contribute to all of the following outcomes:

1. A validated Artificial Intelligence (AI) Foundation Toxicology Model
2. A standardised, transparent weight-of-evidence framework for industry, regulator and academic stakeholders
3. Functional tools, templates, and training materials
4. Enhanced industry and regulator stakeholder confidence in second species waiver applications

Link

Deadline: 1 October 2026, 17:00 Brussels time.

Funding

• Total Budget: up to 9.000.000 EUR
• Amount per project: 4.500.000 EUR
• Number of funded project proposals: 2

This call, under the Digital Europe Programme, funds large-scale pilot projects to deploy and validate trustworthy, European-developed AI and GenAI systems for medical image screening in real clinical settings. The objective is to accelerate adoption of AI in healthcare, particularly for cancer and cardiovascular disease screening, by generating robust clinical, organisational, and cost-efficiency evidence.

Areas

• AI systems for medical image screening in real clinical settings
• Clinical validation and evidence generation for cancer and cardiovascular disease screening at scale.
• Integration of AI into existing healthcare workflows to enable scalable, cross-border adoption.

Link

Opening date: 10 February 2027

Deadline: 13 April 2027 / 22 September 2027

Budget : €63 800 000 – 7/8 projects to be funded

Proposals should address all the following aspects:

• Perform rigorous early stage clinical trial(s) to validate novel or refined healthcare interventions for treatment and/or disease management solutions for patients suffering from the following specific NCDs: cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases. Whenever relevant, existing co- and multimorbidities should be addressed in the trial design.
• Clinical trial(s) should be supported by completed proof-of-concept of clinical safety and efficacy.

• Take into account sex and gender differences in all relevant aspects throughout the research process, and consider stratification criteria such as age, disability, racial or ethnic origin socio-economic status, genetic and epigenetic variations, etc., where relevant.
• Use and/or develop technologies, including digital ones (e.g. (generative) Artificial Intelligence, wearable technologies) to help implement and monitor the long-term efficacy of the intervention(s), as well as manage the disease and/or monitor their progression (e.g. with unobtrusive technologies suitable for patient monitoring at home and in real-world conditions), whilst also ensuring they are bias-free, inclusive, and ethically sound. Hardware and software should be interoperable in line with internationally accepted standards^. The use of virtual human twins could also be considered, where relevant.
• Exploit existing data, health data infrastructures, biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles and contribute to emerging research infrastructures established in the framework of the European Health Data Space (EHDS) when relevant.
• Advance research by leveraging already existing and emerging state-of-the-art research infrastructures as well as results stemming from EU-supported research projects, where applicable.
• HORIZON-HLTH-2027-01-DISEASE-10

Link

Opening date: February 10, 2027

Deadline: April 13, 2027, 2:00 a.m.

Budget :€11 800 000  / 3-4  projects to be funded

In this regard, proposals focused on implementation research should explore implementation strategies on evidence-based interventions, adaptations of interventions and tailored interventions, or initiatives including (though not limited to) those focussed on one or more of the following:

• Policy evaluation to tackle childhood- and/or youth-relevant social, economic, political, structural or commercial determinants of chronic NCD conditions.
• Prevention of NCDs using children and/or young people targeted implementation strategies (e.g. educational strategies, vaccination strategies, promotion of behavioural and lifestyle changes).
• Screening and diagnosis of NCDs (or risk factors) in children and/or young people (in particular use of digital tools).
• Cost effective and patient-centred management of NCDs in children and/or young people (including access to medicines and equipment; integrated care pathways; continuity of care for adolescents with existing non-communicable diseases who “age out” of paediatrics, caregiver health and support, citizen science approaches).

Multiple interventions focus on prevention of NCDs in children and young people, yet relatively few have focussed on strategies for management of chronic conditions in these critical life stages, and a limited number of studies have been carried out to study implementation of these in LMIC contexts or with underserved communities. In this instance it would be anticipated that proposals should explore implementation strategies using the appropriate hybrid design study incorporating effectiveness and implementation research outcomes. Therefore, it may be important to undertake formative research as a part of the proposal to support readiness for implementation.

The proposed implementation research should be focused on one or more evidence-based interventions (or complex interventions), providing existing evidence of the intervention’s effectiveness, cost-effectiveness, sustainability, scalability and potential for long-term health and other impacts (and in what context this evidence has been generated).

Link

Opening date: 10 February 2027

Closing date 1: 13 April 2027

Budget: €38 million

Expected outcome

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products) and enhanced health outcomes by ensuring safer and more effective use of medication.
• Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities.
• Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines.
• Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence.
• Educational programs for healthcare providers and patients benefit from improved awareness and management of polypharmacy and ADRs.

Proposals funded under this topic should address all the following aspects:

• Leverage the role of pharmacogenomics, pharmacokinetics and pharmacodynamics in predicting and preventing adverse drug reactions in situations of multiple medications (three or more drugs administered concomitantly), and propose personalised medicine approaches, such as targeted therapies and biomarker-driven treatment strategies, to reduce the rate of adverse drug reactions and limit multiple medications.
• Maximise the use of technology, such as electronic health records, artificial intelligence and clinical decision support systems, to support safe medication use and prevent adverse drug reactions.
• Address the ethical, regulatory, and implementation challenges associated with integrating personalised medicine into clinical practice to address adverse drug reactions due to the administration of multiple medications.
• Generate evidence on the clinical utility and cost-effectiveness of treatment guided by pharmacogenomics and other relevant biomarkers-based approach, for single drugs and for combinations of drugs.
• Develop and implement strategies, including regulatory science approaches, for efficient integration of project results into daily healthcare.
• Align with similar work in other EU-funded projects or partnerships, such as the co-funded European Partnership for Personalised Medicine, the co-funded European Partnership on Transforming Health and Care System, etc. while avoiding any potential overlaps.

Link

Opening date: 10 February 2027

First deadline: 13 April 2027
Second deadline: 22 September 2027

Budget: €44.2 million – 6/8 projects to be funded 

Expected outcome

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society.” To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Clinical researchers and developers have access to novel predictive biomarkers to guide a more accurate assessment of disease progression and treatment response and tackle the unmet clinical needs of non-communicable chronic diseases.
• Clinicians and healthcare professionals use clinically validated predictive biomarkers for implementing more effective clinical research and personalised medicine with better health outcomes in chronic non-communicable diseases.
• Key stakeholders have access to trustworthy Artificial Intelligence (AI) tools to guide the development of multimodal predictive biomarkers of higher accuracy and clinical value when compared to the established practice.
• The citizens benefit of better health outcomes thanks to improved clinical guidelines and the implementation of effective biomarker-guided clinical research and personalised healthcare.

The proposals should address all the following research and innovation activities:

• Set-up a multidisciplinary collaboration to map and evaluate the available information and data on biomarkers currently used in the clinical setting, candidate biomarkers from past and ongoing clinical studies, which are scientifically proven as clinically relevant to the disease progression and treatment response for the chronic non-communicable diseases under study.
• Adapt and apply of established AI methods rather than developing novel ones from scratch, to deliver novel predictive biomarkers of disease progression and treatment response, by integrating data of currently used and candidate biomarkers, with suitable data from available longitudinal and other relevant clinical studies, including RWD, as necessary.
• Use AI and, where needed, other relevant data and knowledge integration methods, to describe the relationships among different biomarkers and support the robust prioritisation of predictive biomarkers tailored to the characteristics of the patients’ and their disease stage and treatment response.
• Establish a biomarker validation platform to assess the clinical utility of the predictive biomarkers identified.
• Develop a comprehensive exploitation plan for the valorisation of the research outputs and a regulatory strategy to support the alignment to the regulatory requirements for the qualification of the biomarkers and/or AI tools and engage with the regulators in a timely manner.

Link

Deadline: April 13, 2027, 2:00 a.m.

Budget: €39 300 000 (6-8 projects to be funded)

Call : Cluster 1 – Health (Single stage – 2027/1)

Call Identifier : HORIZON-HLTH-2027-01

Expected Outcome:

• Persons with disabilities are empowered and can enjoy their rights to live independently, participate in society and be included in the community on an equal basis with others.
• The scientific community develops innovative solutions with a focus on removing barriers faced by persons with disabilities to live independently and they are provided with community support services where they live in the community.
• Policymakers, health and care services, social and service providers, disability organisations, funders, the scientific community, and other relevant bodies are informed of the research advances and best practices addressing the health and needs of persons with disabilities to support them living independently and being included in society.

Link

Opening: 3 June 2027

Deadline: 22 September 2027

Estimated total Budget: €39.3 million

Expected outcome

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society.” To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Healthcare professionals have access to multi-scale, multi-organ models of individual patients that aim to improve prevention and diagnosis in high disease burden areas.
• Health professionals benefit from enhanced knowledge of complex diseases and co-morbidities by recourse to multi-scale, multi-organ models.
• Patients with diverse characteristics (e.g. of any sex, age group, racial or ethnic origin) benefit from improved, integrated and personalised prevention and diagnostics tools.
• Health professionals and patients benefit from the use of “Virtual Human Twin” (VHT) models which enable integration of other preventive and diagnostic tools and modalities.

The proposals should address all the following activities:

• Select clinical use cases to deliver multi-disciplinary, high impact solutions requiring multi-organ, multi-scale approaches to modelling complex pathophysiology over time, as a basis from where prevention and diagnosis of diseases with high morbidity and mortality could be enhanced.

• Building on current approaches, standards, data repositories (e.g. biobanks, environmental data, others) and modelling assets (e.g. those of the EDITH CSA and the Platform for Advanced VHT Models), and new data if relevant, design, develop, extend and validate multi-organ, multi-scale, dynamic computational models that accurately simulate a person’s health and disease states, as necessary.
• Evaluate, select, extend and validate diverse modelling methodologies, resulting in integrated, advanced, interoperable, patient-specific VHT models that can integrate diverse data sources and methodologies, addressing the chosen clinical use case requirements.
• Demonstrate integration of these models with other advanced preventive and diagnostic modalities, tools and techniques enabling integration across pathways.
• Generate evidence, including clinical validation, that the solutions deliver clinically meaningful decision support, addressing use case requirements.

Link

Opening: 3 June 2027

Deadline: 22 September 2027

Estimated total Budget: €2.9 million

Expected outcome

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society.” To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Researchers and innovators benefit from an improved understanding of how to develop and use the next generation of frontier Artificial Intelligence (AI) models for healthcare, including how to leverage AI Factories and how to combine and expand the capabilities of existing foundation models towards inclusive and personalised medicine.
• Researchers and innovators benefit from an improved understanding of how to leverage highly heterogeneous and multimodal health data spanning a range of anatomical scales (i.e. the micro to the macro level).
• Multidisciplinary stakeholders have access to a collaboratively created roadmap for developing the next generation of frontier AI models for healthcare, towards Artificial General Intelligence (AGI) for healthcare.

Proposals should include all the following coordination and support activities, ensuring multidisciplinary approaches and a broad representation of stakeholders in the consortium (e.g. healthcare professionals, patients, biomedical scientists, AI developers, data engineers, ethics experts)

Link

Deadline: September 22, 2027, 2:00 a.m

Budget: €39 300 000

Expected Outcome:

• Biomedical scientists from academia and industry will gain access to entire bio-printing units designed to regenerate human tissue.
• Healthcare professionals acquire information on the safe and effective use of equipment enabling advanced therapies with bio-printed human tissue.
• Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need.
• Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.

Researchers should work in multidisciplinary teams with engineers, biomedical scientists, cell biologists and medical doctors. Proposals should be based on the use of human cells and address all the following activities:

• Develop or improve existing bioprinting equipment that comprises all steps of the bio-printing suite to print bio-constructs with high cell-density for improved vascularisation and faster repair of the defect in the body.
• Scale-up the chosen bio-printing technology to a Good Manufacturing Practices (GMP)^[1] conform/compliant manufacturing process.
• Perform all necessary regulatory work enabling the conduct of clinical studies and assess the clinical value of the developed bio-printing technology in first in-human studies.

Link

There is a single annual competition for Research Grant awards. Review of research grant applications is performed in two stages: 

1. Applicants must first submit a letter of intent via the HFSP website, with a deadline around the end of March/beginning of April. After review of the letters of intent, invitations are issued in early July to the teams selected to submit full applications.
2. Full proposals are then due around the middle of September, on invitation only.

HFSP Research Grants support innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries (see guidelines).

Research grants are provided for teams of scientists who are based in different countries and wish to combine their expertise in innovative approaches to questions that could not be answered by individual laboratories. Preliminary results are not required and applicants are expected to develop new lines of research through the research collaboration.

Awarded to teams of independent researchers at any stage of their careers. The research team is expected to develop new lines of research through the collaboration. Applications including independent investigators early in their careers are encouraged.

Link

There is a single annual competition for Research Grant awards. Review of research grant applications is performed in two stages: 

1. Applicants must first submit a letter of intent via the HFSP website, with a deadline around the end of March/beginning of April. After review of the letters of intent, invitations are issued in early July to the teams selected to submit full applications.
2. Full proposals are then due around the middle of September, on invitation only.

All team members are expected to direct a research group (however small) and must have a doctoral degree (PhD, MD or equivalent). They must be in a position to initiate and direct their own independent lines of research. The HFSP award is not intended to create scientific independence, this is a decision of the research institute prior to the application.

Link

Deadline: will be communicated soon – in 2027 (beginning)

Budget: For EIC Pathfinder Open, grants of up to EUR 3 million are typical, though larger amounts can be requested if justified. For EIC Pathfinder Challenges, grants can be up to EUR 4 million.

The EIC Pathfinder is designed to support the earliest stages of scientific, technological, or deep-tech research and development. Its primary objectives are:

1. Developing Scientific Foundations: To underpin breakthrough technologies that can disrupt existing markets or create new ones.
2. High-Risk/High-Gain Research: Encouraging projects that involve significant risk but have the potential for substantial rewards.
3. Interdisciplinary Collaboration: Promoting collaboration across diverse scientific and technological disciplines to achieve innovative breakthroughs.

The EIC Pathfinder is divided into two main components:

• EIC Pathfinder Open

The EIC Pathfinder Open provides support for projects in any field of science, technology, or application without predefined thematic priorities. It targets early-stage development of future technologies, emphasizing high-risk/high-gain science-towards-technology breakthrough research. The key features include:

• Ambitious Vision: Projects should have a long-term vision for a radically new technology with transformative potential.
• Scientific Breakthrough: Proposals should outline a concrete, novel, and ambitious science-towards-technology breakthrough.
• High-Risk/High-Gain Approach: The research approach should be innovative and potentially risky, aiming for significant advancements.

• EIC Pathfinder Challenges

The EIC Pathfinder Challenges focus on predefined thematic areas with specific objectives. These challenges aim to create coherent portfolios of projects that collectively achieve the desired outcomes. Each challenge is overseen by a dedicated Programme Manager who guides the projects towards common goals. The key features include:

• Specific Objectives: Each challenge has defined goals and expected outcomes.
• Portfolio Approach: Projects within a challenge are expected to interact and collaborate, leveraging each other’s strengths.
• Dedicated Programme Managers: Programme Managers play a proactive role in steering the projects towards successful outcomes.

Link

Opening date: 28/05/2026

Closing date 1: 27/08/2026

Budget: € 747 000 000 (projected number of awards: 294)

Are you an established, leading principal investigator who wants long-term funding to pursue a ground-breaking, ambitious project? The ERC Advanced Grant could be for you.

Who can apply?

Applicants for the ERC Advanced Grants – called Principal Investigators (PI) – are expected to be active researchers who have a track-record of significant research achievements.

The Principal Investigators should be exceptional leaders in terms of originality and significance of their research contributions. No specific eligibility criteria with respect to the academic requirements are foreseen.

Criteria
Applications can be made in any field of research.
The ERC’s grants operate on a ‘bottom-up’ basis without predetermined priorities.

Advanced Grants may be awarded up to € 2.5 million for a period of 5 years. (pro rata for projects of shorter duration). However, an additional € 1 million can be made available to cover eligible “start-up” costs for researchers moving from a third country to the EU or an associated country and/or the purchase of major equipment and/or access to large facilities and/or other major experimental and field work costs.

To further encourage the submission of excellent proposals by Principal Investigators currently based in non-associated third countries, the ERC has decided to double the amount of additional funding that can be awarded to Advanced Grant applicants moving to the EU or an associated country to take up their ERC grant. In this case, the maximum additional funding shall be € 2 million.

An ERC grant can cover up to 100% of the total eligible direct costs of the research plus a contribution of 25% of the total eligible costs towards indirect costs.

Link

The Rare Epilepsy Partnership Award (1 year / $100,000) will support the development of necessary research tools, techniques, model systems, and data collection platforms to stimulate and accelerate research on rare epilepsies. Each award will be co-funded by CURE Epilepsy and one or more of the rare epilepsy advocacy groups (partners) identified in the Request For Proposals. Applications must focus on one or more of the specific rare epilepsies that are represented by each group as well as address CURE Epilepsy’s mission to cure epilepsy.

The first ERDERA Clinical Trials Call will be soon available.

Link 

Clinical Trials Call funds controlled clinical research studies undertaken in humans to establish or confirm the safety and effectiveness of therapeutic interventions. These will benefit from ERDERA support for regulatory and methodological aspects.

Deadline: Applications accepted throughout the year

Link 

Travel costs and stipend

EMBO Scientific Exchange Grants contribute towards travel costs and subsistence of the fellow but not of any dependents. The subsistence rate depends on the country being visited. Research Exchange Grants do not provide additional funding for courses, conference travel, bench fees or overheads. EMBO does not cover visa costs.

Duration of support

The grants are intended for visits of one week (seven days) up to three months (90 days). Awarded applicants can stay on their research visit for an additional three months (maximum), however, EMBO will not provide funding for this extended period. It is possible to apply directly for more than three months (up to six), but the EMBO grant must be used for the first three months of the visit.

Budget: Projects may be funded at the $25,000, $50,000, or $75,000 level. The project duration is one or two years.

No deadline

Link

The Lennox-Gastaut Syndrome Foundation (LGS Foundation) is a non-profit organisation based in the United States. Its mission is to improve the lives of individuals affected by Lennox-Gastaut Syndrome, a rare form of childhood-onset epilepsy, through research, programmes and education. Projects may be on any novel topic in LGS but must be directly relevant to LGS, which is characterized by specific seizure types and hallmark EEG features.

The LGS Foundation Cure LGS 365 Research Grants provide funding to seed new basic, translational, and clinical Lennox-Gastaut Syndrome research projects.

Applications must be submitted by email. Letters of Intent (LOIs) may be submitted at any time; there are no deadlines. Selected applicants are invited to submit a full proposal.

Link

Deadlines: Project applications can be submitted until

• 1 February  for the summer meeting of the foundation committees in June
• 1 September for the winter meeting of the foundation committees in February

of each year.

In accordance with one of the desires of the donors, special attention is devoted by the foundation institutions to medical research. At present the foundation is focusing its support on the field of “Molecular causes in the development of illnesses”.  This programme supports molecular biological studies of illnesses whose development is based on genetic defects or with which gene variants contribute to the development of complex illnesses.

In the area of “Molecular causes in the development of illnesses”, molecular biological studies of illnesses are supported whose development is primarily based on genetic defects or whose gene variants contribute to the development of complex illnesses.

Studies may be performed on cell culture and/or animal models, but should at least in part be performed on human tissue specimens and/or cells bearing relevance to illnesses. This only applies for applications submitted for support of projects.

• Project proposals are only accepted from researchers that have a Ph.D. and relevant experience in the priority field of research. They should generally have two to four years’ experience in post-doctoral research and want to set up or expand a small working group of their own with the support of the Foundation. The position of the applicant should be funded by the host research Institute.
• It is generally not possible to obtain funding for one’s own position.
• Firmly established researchers and scientists (holders of chairs, directors of clinics) are not eligible for support of projects.

The following projects are assigned preference:

• The functional analysis of genes, gene products and their signal transduction pathways for monogenic and complex genetic illnesses in vitro and in vivo, whereby the work plan should also contain studies on human tissue specimens and/or cells
• The characterisation of cell and animal models that have already been established for the study of genetic illnesses (with molecular biology methods)
• The analysis of predisposing genes or therapies which modify illnesses (‘personalised medicine’) if this holds out the promise of additional findings being generated on the mechanistic causes of disease formation

Support is not provided for:

• Purely methodological studies
• Descriptive genetic studies of populations as well as linkage and association studies
• Purely drug screening projects
• Research projects without any direct connection to an illness
• Research projects involving the development of an animal model that is to be studied in the grant period applied for
• Research projects that do not involve any studies on human tissue specimens and/or cells bearing relevance to illnesses
• Research projects relating to infectious diseases
  Diagnostic and primarily therapy-oriented projects

TYPES OF COSTS

PERSONNEL COSTS

Complete personnel costs can be applied for in the case of research staff with doctoral degrees under

TVL-E13. In the case of research staff who do not have doctoral degrees, their pay is generally based on

65% of a TVL-E13-position. In countries other than Germany, the personnel costs are to be stated

according to the salary costs arrangements applicable there, i.e. total wage costs including the employer’s

share as a total sum.

In the case of applying for personnel costs for clinician scientists, the foundation assumes that the

planned staff will be put on leave at least 80 per cent of their working time at the clinic. Confirmation of

this from the clinic is to be submitted with the application.

Non-academic personnel are paid at the appropriate TVL level.

Student helpers or research assistants should be paid according to the rates prevailing at the institution

involved; the foundation is to be notified hereof through the budget plan accompanying the application.

TRAVEL COSTS

Funds to defray travel costs that are directly connected with the project can be applied for. In addition to

reasonable travel and overnight accommodation costs, up to € 28 a day can be granted to defray the costs

of meals when traveling within Germany (rail travel 2nd class or air travel economy class).

In the case of travel abroad, the daily or monthly rates for the respective country of travel can be applied

for to defray overnight accommodation and meal costs.

WHAT CANNOT BE APPLIED FOR

› Staff resources for the own post

› Financial resources for construction work

› Financial resources to procure office furnishings and equipment that are usually part of the basic

furnishings at universities and institutes

› Generally, no financial resources are granted to defray overhead costs

The FamilieSCN2A Hodgkin-Huxley Grant program was created to honor the achievements of Dr. Alan Hodgkin and Dr. Andrew Huxley and their innovative modeling of action potentials, as well as their contributions which laid the groundwork for neuroscience research on the molecular, cellular, and circuit levels.

Unsolicited, year-round LOIs accepted. Full application invitations on a rolling basis as long as funds are available.

Link

Link

These research grant awards are intended for established, experienced, independent investigators affiliated with a research or academic institution whose proposed projects seek to investigate hypotheses directly related to hypothalamic hamartoma syndrome. Proposals are scored based on the quality of preliminary data, research design, feasibility, investigator’s qualifications, and overall impact.

Investigators applying for a research grant should ensure their proposed project addresses the needs of the hypothalamic hamartoma syndrome community and Hope for HH’s mission to support research toward better understanding, improved treatments and ultimately a cure for hypothalamic hamartoma syndrome.

Eligibility:

Applicants should be affiliated with a research or academic institution (excluding for-profit companies), may be US or foreign based, established in their field, and in good standing with their institution.

Our research priority areas include:

• Research that helps identify patient trends, characteristics, epidemiology, or other clinical aspects of hypothalamic hamartoma syndrome and/or its comorbidities.
• Research that will encourage the development of novel therapies to eliminate or prevent seizure progression or halt the progression of other comorbidities associated with hypothalamic hamartoma syndrome.
• Research that helps to understand, predict, and prevent SUDEP